Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | M1069 |
Synonyms | |
Therapy Description |
M1069 is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and decrease tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3499). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M1069 | M-1069|M 1069 | Adenosine Targeting 23 | M1069 is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and decrease tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3499). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05198349 | Phase I | M1069 | First in Human Study of M1069 in Advanced Solid Tumors | Terminated | USA | CAN | 0 |